⌕
Kiniksa Pharmaceuticals International · KNSA · Nasdaq
Tenet 55 · Mixed
Compare
$95.11+0.93%At closeTenet 55 · Mixed
$95.11+0.88 (+0.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kiniksa Pharmaceuticals International (KNSA) Stock

Kiniksa Pharmaceuticals International (KNSA) closed at $95.11 on Nov 17, 2026; its Tenet Score is 55 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

11 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$95.11
Nov 17, 2026
Market cap
$7.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
73.0×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
37.02 – 99.31
low → high · as of close, Nov 16, 2026
Tenet Score
55/100
Mixed · 340 Healthcare peers

Industry: Drugs

Kiniksa Pharmaceuticals International Plc. scores 55/100. Mixed. Strongest on financial health and quality, value is the soft spot, trading at 73× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
55/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
18
Quality
70
Health
74
Growth
60

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityBHealthBGrowthCMomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
10.4×
Sep 30, 2026 balance sheet
P/S
7.8×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
18%
TTM through Sep 30, 2026
Operating margin
11.4%
fiscal 2025, before interest and tax
Net margin
11.6%
TTM through Sep 30, 2026
Current ratio
3.91
Sep 30, 2026 balance sheet
Net debt / EBITDA
−4.3×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Kiniksa Pharmaceuticals International Plc.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its produc…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 78 US ETFs · top wrappers by weightSee all ETFs holding KNSA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Kiniksa Pharmaceuticals International in?

Kiniksa Pharmaceuticals International is in the Healthcare sector and the Drugs industry.

What is Kiniksa Pharmaceuticals International's Tenet Score?

Kiniksa Pharmaceuticals International's Tenet Score is 55 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.